A U.S. judge on Friday allowed Purdue Pharma to immediately challenge its rejection of legal protections for members of the Sackler family who own the maker of OxyContin, which were a major part of its bankruptcy reorganization plan.

U.S. District Judge Colleen McMahon’s ruling means Purdue will have another chance to keep intact a $ 4.5 billion opioid litigation settlement at the heart of the company’s plan. She gave Purdue until Jan. 17 to file the appeal with the New York-based 2nd US Court of Appeals.

McMahon overturned a bankruptcy judge’s order approving the deal in December. The settlement provides for so-called non-debtor discharges that protect the Sacklers from future opioid-related lawsuits.

Purdue filed for bankruptcy in 2019 in the face of thousands of lawsuits accusing him and the Sacklers of fueling the opioid epidemic with deceptive marketing.

The Sacklers, who denied any wrongdoing, paid US $ 4.5 billion in settlement in return for the releases.

As part of Purdue’s reorganization plan, settlement funds would be directed to opioid reduction programs.

(Report by Maria Chutchian, edited by Alexia Garamfalvi and Bill Berkrot)

jQuery (document) .ready (function () {window.fbAsyncInit = function () {FB.init ({appId: ‘404047912964744’, // App ID channelUrl: ‘ /channel.html ‘, // Channel file state: true, // check the connection state cookie: true, // enable cookies to allow the server to access the xfbml: true session // parse XFBML }); FB.Event.subscribe (“edge.create”, function (response) {Tracking.trackSocial (‘facebook_like_btn_click’);});

// START: Facebook clicks on the different button FB.Event.subscribe (“edge.remove”, function (response) {Tracking.trackSocial (‘facebook_unlike_btn_click’);}); };

var plusoneOmnitureTrack = function () {$ (function () {Tracking.trackSocial (‘google_plus_one_btn’);})} var facebookCallback = null; requireDependency (‘’, facebookCallback, ‘facebook-jssdk’); });

Disclaimer! NewsConcerns is an automatic aggregator of all media in the world. In each content, the hyperlink to the main source is specified. All trademarks are the property of their rightful owners, all documents are the property of their authors. If you are the content owner and do not want us to publish your materials, please contact us by email – [email protected]. Content will be removed within 24 hours.